These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 33047900)

  • 21. Ferroptosis-related gene signature as a prognostic marker for lower-grade gliomas.
    Zheng Y; Ji Q; Xie L; Wang C; Yu CN; Wang YL; Jiang J; Chen F; Li WB
    J Cell Mol Med; 2021 Mar; 25(6):3080-3090. PubMed ID: 33594759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
    Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
    Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
    Xing L; Zhang X; Tong D
    DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Nomogram for Predicting Individual Prognosis of Patients with Low-Grade Glioma.
    Zhao YY; Chen SH; Hao Z; Zhu HX; Xing ZL; Li MH
    World Neurosurg; 2019 Oct; 130():e605-e612. PubMed ID: 31319188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
    Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
    BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TGF-β Score based on
    Zhang W; Yan Z; Zhao F; He Q; Xu H
    Recent Pat Anticancer Drug Discov; 2024; 19(5):610-621. PubMed ID: 37718518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Critical m
    Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
    Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic relevance and validation of ARPC1A in the progression of low-grade glioma.
    Dai J; Gao J; Dong H
    Aging (Albany NY); 2024 Jun; 16(14):11162-11184. PubMed ID: 39012280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
    Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
    Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An independently validated survival nomogram for lower-grade glioma.
    Gittleman H; Sloan AE; Barnholtz-Sloan JS
    Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.
    Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B
    Front Oncol; 2020; 10():1257. PubMed ID: 32793502
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
    Zhang C; Liu H; Xu P; Tan Y; Xu Y; Wang L; Liu B; Chen Q; Tian D
    BMC Cancer; 2021 Mar; 21(1):251. PubMed ID: 33750353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.